Public pda.org

Quality Management Maturity (QMM) Case Study: MSD

Niraj Mehta, PhD

Executive Director, Global Quality Transformation

MSD







Agenda:

Cost of Quality

MSD QMM Journey

QMM Qualitative Assessment Overview

QMM Quantitative Assessment Overview

Conclusions



Business focus shift from "Strategy" to "Culture" due to positive indicators





Our findings on increased retention show that the

average SSP 500 company would see a savings

of \$156M in turnover costs annually if employees

were to describe its culture as healthu.1



For every 5,000 employees, moving from the bottom to the top quintile would save a company \$67 million annually

Harvard Business Review April 2014 "Creating a Culture of Quality" CEB (Corporate Executive Board) Results of Two Years of Research

\$156M

From Grant Thornton 2019: Return on Culture

Self-described world-class*
organizations are more apt to
increase investment in quality, with
66% of those organizations planning
to increase investment in quality
programs in the next 18 months.


http://asq.org/culture-of-quality/

Companies ranked in the top 20% in terms of quality culture reported 46% fewer mistakes in their daily work resulting in a saving of \$67M per 5K employees

From **Harvard Business Review April 2014**: Creating a Culture of Quality. Ashwin Srinivasan & Bryan Kurey CEB

Since the launch of our Quality Driven Management program in 2008 ... we have been able to achieve hundreds of millions of dollars of cost savings.


CULTURE CULTURE STATES OF THE STATES OF THE







Why should we Care about QMM? Cost of Reactive vs Proactive Quality



^{*} Graphic presented during PDA 2024 Supply Chain Resilience & Quality Management Maturity Conference (09/19/2024): "Investing in Quality," Sun Pharma.





Reactive Quality Cost in Terms of Enforcement Actions

- Hypothetical-Five inspection observations citing the following subsystems:
 - Complaint Handling and MDR Reportability
 - CAPA
 - **Design Controls**
 - **Process Validation**
 - Internal Audit 0
- 6-month remediation plan (TOTAL COST: \$1,526,000)
 - Salary costs (~\$280,000+)
 - Ex-FDA Consultants (~\$120,000+)
 - Product recalls 3 lots / approx. 350 units @ \$1,800 each (\$630,000)
 - Finished goods scrap 1 lot / 120 units @ \$1,800 each (\$216,000)
 - New production equipment + process validation package (\$180,000)
 - New CAPA software module (\$100,000 to implement + \$50,000 annually)









MSD QMM Implementation Strategy

Qualitative Assessment

- Based upon the Parenteral Drug Association's (PDA) **Quality Culture** Maturity Model
- Customized for shop floor and managers / supervisors
- Output summarized in an interactive dashboard


Quantitative Assessment

- Leveraged our company data lake to access Quality Council metrics as well as other data sources
- Created a quantitative risk level per site with ability to narrow down to individual metrics
- Output summarized in an interactive dashboard















Foundation of Qualitative QMM Assessment

MSD Qualitative Model (aligned with PDA Quality Culture Maturity Model)*

Category	Attributes	Elements
Employee Ownership and Engagement	Understanding Quality Goals	Impact on Product Quality Patient Impact
	Staff Empowerment and Engagement	Process Ownership and Engagement
		QMS Processes
Continuous Improvement	CAPA Robustness	Root Cause
		Human Error
	Clear Quality Objectives and Targets	Continuous Improvement
Technical Excellence	Utilization of New Technologies	Manufacturing Technologies
	Maturity of Systems	Training
		Business Conduct
		Quality Risk Management
Leadership Commitment	Commitment to Quality	Accountability and Quality Planning
	Enabling Resources	Safety Program
		Rewards & Recognition
		Feedback & Staff Development
Communication & Collaboration	Quality Communications	Quality Communications
	Management Review and Metrics	Management Reviews
		Metrics
	Internal Stakeholder Feedback	Internal Stakeholder Feedback
		Quality Culture Survey


^{*}Reach out to PDA Training (training@pda.org) for more information on the Quality Culture Maturity Model training program

Evolution of FDA model: Practice Areas and Elements **Prototype of Protocol:**

Examples of Assessment Practice Areas

Practice Areas will be assessed according to a defined rubric. Supply Planning Understanding Management CAPA* & Demand Patient Impact Governance Activities Forecasting & Quality Goal Manufacturing Resource Process Change Rewards & Strategy & Management Optimization Management Recognition Operations

*CAPA - Corrective Action and Preventive Action **Five QMM Practice Areas**




^{*}Top graphic presented during GMP by the Sea (08/15/2023): "Realizing Supply Chain Resiliency through a Commitment to Quality" U.S. FDA. Slide 11. Bottom graphic presented during PDA 2024 Supply Chain Resilience & Quality Management Maturity Conference (09/19/24): "An Overview of CDER's QMM Program," U.S. FDA, Slide 20.





QMM Qualitative Assessment Details

- Dashboards are created for each site
- Individual metrics can be aggregated to the Attribute and then the Category level for better action targeting
- Data can analyze data by:
 - IPT/End-to-End
 - Functional Area
 - Length of service
- Optional comments are collected per question for additional insight and provided via Excel









QMM Qualitative Assessment Output and Next Steps

- After completing the assessment, sites will:
 - 1. Identify opportunity areas using the dashboard
 - 2. Determine whether the trend is for the entire site, or a sub-section of the site
 - 3. Develop an action plan that is embedded in the site's governance structure (e.g., Hoshin planning process)
- Example: A site reviewed their assessment data for individual laboratories. Example actions:
 - Continuous Improvement: Installed a six sigma "model area" with redesigned tier process to improve problem escalation
 - Manufacturing Equipment: Implemented improvements to the asset reliability program regarding laboratory equipment
 - Feedback and Staff Development: Implemented a new GEMBA process to ensure better adherence to shop floor presence commitments






Mait Mhat about Quality Matr

Wait, What about Quality Metrics? QM ≠ QMM but QM informs QMM

- FDA has long shown an interest in broader utilization of QM, QMM is part of this evolution
- Industry's early focus on QMM has been on the assessment of quality culture, but this is not the complete picture
- The best approach will be a combination of qualitative and quantitative strategies





*Graphic presented during FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting (11/2/22): Slides 27 and 28. https://www.fda.gov/media/162821/download.





QMM Quantitative Assessment Overview

- Focuses on the proactive signals from QM
- An interactive dashboard displays a manufacturing site's compliance risk versus impact
- No manual calculations are required for the model to function
- Impact is viewable through multiple views that provide different methods of segregation depending on the audience






pda.org



QMM Quantitative Assessment Overview (continued)

The view at right shows how relative risk can change

- Overall risk can go up or down the y-axis as inputs are mitigated or new risks emerge
- An impact score on the x-axis helps prioritize constrained resources across the network







QMM Quantitative Assessment Factors

- An overall risk score is a culmination of four factors:
 - 1. Inspection Factor: Incorporates measures on health authority observation quantities, global auditing outcomes, overdue and extended CAPAs
 - 2. Manufacturing Factor: Incorporates measures on calibration and maintenance, batch release, batch acceptance, and invalidated OOS
 - **3. External Defects Factor**: Incorporates measures such as BPDRs, FARs, complaints, and recalls
 - **4. Deviation Factor**: Incorporates measures such as CAPA strength and recurrent investigation rate
- Once a factor is highlighted for review, explore further with advanced analytical tools in alignment with FDA's QMM umbrella





Conclusions:

- Companies should NOT invest in Quality Culture because it is a U.S. FDA initiative but rather because it's the RIGHT thing to do.
- Establishing proactive qualitative and quantitative measures to identify Quality compliance issues will save company resources in the long term.
- QMM is a tool used to measure a company's Quality Culture.



quality-management-maturity-model-quality-culture-v2-582x279.jpg (582×279) (pharmout.net)



pda.org



Acknowledgements:

Adam Caruso

Thank You!

